1. Medtech Insight
  2. >>Policy & Regulation

Trump Administration Drops Tariffs On Certain Medtech Imports From China

The Trump administration has decided to waive tariffs on certain medtech products imported from China that could help the US combat the ongoing COVID-19 crisis.

USA and China flag print screen on like hand symbol with white background.It is symbol of economic tariffs trade war and tax barrier between United States of America and China.

The Office of the US Trade Representative has dropped tariffs for certain imported medical devices, including personal protective equipment (PPE), in the ongoing trade war with China. The announcement comes as the country grapples with the global coronavirus crisis.

On 6 March, the Trump administration announced it is dropping tariffs on a slew of products including sanitation wipes,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Compliance

More from Policy & Regulation

MHRA’s Tallon Hails PMS Regulation As Start Of UK Device Framework Transformation

 
• By Ashley Yeo

16 June marked the first major new regulatory instrument in the UK’s post-Brexit transition to a standalone device regulatory system for Great Britain.

Increasing Safety Concerns Spur Scrutiny of Device Plastics Use

 
• By Elizabeth Orr

With new regulations limiting the use of plastics popping up worldwide, the medtech industry sees arguments on both sides. Some argue hasty bans of PFAS ("forever chemicals") would harm patients, while others say phthalates should be phased out to protect the public.

With LDT Rule DOA, Could FDA Shift Focus To RUOs?

 
• By Brian Bossetta

Now that the US FDA has chosen not to appeal a March ruling effectively killing the agency’s efforts to regulate lab-developed tests as medical devices, will the agency adopt a different strategy to flex its regulatory muscle?